Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteonectin | 12 | 2020 | 17 | 2.900 |
Why?
|
| Ovarian Neoplasms | 11 | 2019 | 114 | 2.880 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2020 | 196 | 1.700 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 627 | 0.940 |
Why?
|
| Carcinoma | 3 | 2012 | 97 | 0.860 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 155 | 0.740 |
Why?
|
| Endothelin-1 | 2 | 2012 | 23 | 0.700 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 2 | 2012 | 3 | 0.680 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 72 | 0.670 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 196 | 0.670 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2012 | 70 | 0.630 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 174 | 0.620 |
Why?
|
| Neoplasms | 2 | 2020 | 791 | 0.600 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 772 | 0.580 |
Why?
|
| Adipocytes | 1 | 2019 | 85 | 0.560 |
Why?
|
| Peritoneal Neoplasms | 3 | 2012 | 265 | 0.550 |
Why?
|
| Lung Neoplasms | 2 | 2012 | 452 | 0.520 |
Why?
|
| Mice | 13 | 2020 | 2691 | 0.510 |
Why?
|
| Animals | 17 | 2020 | 8544 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 273 | 0.490 |
Why?
|
| Macrophages | 3 | 2012 | 216 | 0.460 |
Why?
|
| Disease Progression | 5 | 2020 | 633 | 0.460 |
Why?
|
| Cell Adhesion | 4 | 2012 | 116 | 0.420 |
Why?
|
| Mice, Knockout | 5 | 2020 | 484 | 0.390 |
Why?
|
| Glycoproteins | 1 | 2013 | 44 | 0.380 |
Why?
|
| Signal Transduction | 4 | 2020 | 765 | 0.370 |
Why?
|
| Receptors, Endothelin | 1 | 2012 | 6 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 6 | 2020 | 834 | 0.370 |
Why?
|
| Versicans | 1 | 2012 | 5 | 0.370 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2012 | 6 | 0.370 |
Why?
|
| Inflammation | 3 | 2012 | 557 | 0.340 |
Why?
|
| Cell Proliferation | 6 | 2019 | 628 | 0.340 |
Why?
|
| Humans | 20 | 2020 | 34474 | 0.330 |
Why?
|
| Integrins | 2 | 2007 | 45 | 0.320 |
Why?
|
| Mice, Nude | 5 | 2018 | 290 | 0.320 |
Why?
|
| Female | 15 | 2020 | 21490 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2009 | 40 | 0.310 |
Why?
|
| Coculture Techniques | 3 | 2019 | 86 | 0.300 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 90 | 0.300 |
Why?
|
| Epithelial Cells | 2 | 2007 | 148 | 0.280 |
Why?
|
| Ascitic Fluid | 1 | 2007 | 10 | 0.270 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 325 | 0.260 |
Why?
|
| Cell Communication | 1 | 2007 | 42 | 0.250 |
Why?
|
| Lysophospholipids | 1 | 2007 | 27 | 0.250 |
Why?
|
| Chemokine CCL2 | 3 | 2012 | 51 | 0.230 |
Why?
|
| Antibodies, Protozoan | 1 | 2004 | 1 | 0.220 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2004 | 3 | 0.220 |
Why?
|
| Tears | 1 | 2004 | 2 | 0.220 |
Why?
|
| Acanthamoeba Keratitis | 1 | 2004 | 2 | 0.220 |
Why?
|
| Acanthamoeba | 1 | 2004 | 3 | 0.220 |
Why?
|
| Urothelium | 2 | 2016 | 67 | 0.210 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 135 | 0.210 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 76 | 0.200 |
Why?
|
| Prostatic Neoplasms | 2 | 2019 | 498 | 0.200 |
Why?
|
| Prognosis | 3 | 2012 | 1603 | 0.190 |
Why?
|
| Receptor, Endothelin A | 2 | 2012 | 4 | 0.180 |
Why?
|
| Paclitaxel | 2 | 2019 | 73 | 0.180 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 118 | 0.170 |
Why?
|
| Base Sequence | 2 | 2013 | 264 | 0.170 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 107 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2010 | 545 | 0.170 |
Why?
|
| Ovary | 2 | 2019 | 69 | 0.170 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 231 | 0.170 |
Why?
|
| RGS Proteins | 1 | 2020 | 18 | 0.170 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2020 | 9 | 0.160 |
Why?
|
| U937 Cells | 2 | 2012 | 8 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 19 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 27 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 43 | 0.150 |
Why?
|
| Homeostasis | 1 | 2020 | 137 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 103 | 0.150 |
Why?
|
| Blotting, Western | 3 | 2012 | 328 | 0.150 |
Why?
|
| Omentum | 1 | 2019 | 26 | 0.150 |
Why?
|
| Silicon Dioxide | 1 | 2018 | 10 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2020 | 265 | 0.140 |
Why?
|
| Carboplatin | 1 | 2018 | 55 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 152 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 593 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2018 | 57 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2019 | 484 | 0.120 |
Why?
|
| Cell Survival | 2 | 2007 | 304 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2007 | 257 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2007 | 118 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 281 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 180 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 1118 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2019 | 264 | 0.110 |
Why?
|
| Adenoma | 1 | 2015 | 36 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 118 | 0.110 |
Why?
|
| Cell Movement | 2 | 2007 | 180 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 215 | 0.100 |
Why?
|
| Nitrosamines | 1 | 2013 | 11 | 0.100 |
Why?
|
| Galectins | 2 | 2003 | 6 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 26 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2016 | 146 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 56 | 0.090 |
Why?
|
| Receptor, Endothelin B | 1 | 2012 | 5 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2012 | 4 | 0.090 |
Why?
|
| Capillary Permeability | 1 | 2012 | 18 | 0.090 |
Why?
|
| Clodronic Acid | 1 | 2012 | 5 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 52 | 0.090 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 36 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2012 | 63 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 165 | 0.090 |
Why?
|
| Transfection | 1 | 2012 | 216 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2010 | 22 | 0.080 |
Why?
|
| Mice, Mutant Strains | 2 | 2007 | 56 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 80 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 123 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2009 | 20 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 16 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2009 | 62 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 77 | 0.080 |
Why?
|
| Gene Expression | 1 | 2010 | 362 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 84 | 0.080 |
Why?
|
| Cytokines | 1 | 2010 | 269 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 319 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 389 | 0.070 |
Why?
|
| Cystectomy | 1 | 2009 | 110 | 0.070 |
Why?
|
| Epithelium | 1 | 2008 | 32 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 23 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2007 | 1 | 0.070 |
Why?
|
| Dinoprost | 1 | 2007 | 11 | 0.070 |
Why?
|
| Metalloendopeptidases | 1 | 2007 | 12 | 0.070 |
Why?
|
| Hypertension, Renal | 1 | 2007 | 29 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 17 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2007 | 57 | 0.060 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2007 | 7 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2007 | 23 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 38 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 197 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 110 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2007 | 244 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 98 | 0.060 |
Why?
|
| Antigens, Protozoan | 1 | 2004 | 1 | 0.060 |
Why?
|
| Immunity, Mucosal | 1 | 2004 | 7 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 15 | 0.060 |
Why?
|
| Corneal Stroma | 1 | 2004 | 6 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 260 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 50 | 0.050 |
Why?
|
| Wound Healing | 2 | 2003 | 190 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 231 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2004 | 83 | 0.050 |
Why?
|
| Neutrophils | 1 | 2004 | 122 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 276 | 0.050 |
Why?
|
| Azacitidine | 2 | 2016 | 29 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2004 | 438 | 0.050 |
Why?
|
| Cornea | 1 | 2003 | 19 | 0.050 |
Why?
|
| Galectin 1 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 2 | 0.050 |
Why?
|
| Galectin 3 | 1 | 2002 | 5 | 0.050 |
Why?
|
| Oxotremorine | 1 | 2020 | 4 | 0.040 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2020 | 22 | 0.040 |
Why?
|
| Cystoscopy | 1 | 2020 | 28 | 0.040 |
Why?
|
| Urinalysis | 1 | 2020 | 27 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 48 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 56 | 0.040 |
Why?
|
| Metabolome | 1 | 2020 | 39 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 79 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 65 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2020 | 71 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 16 | 0.040 |
Why?
|
| Glucose | 1 | 2020 | 194 | 0.040 |
Why?
|
| Male | 4 | 2020 | 20697 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 612 | 0.040 |
Why?
|
| Tomography | 1 | 2018 | 6 | 0.040 |
Why?
|
| Porosity | 1 | 2018 | 41 | 0.040 |
Why?
|
| Insulin | 1 | 2020 | 394 | 0.040 |
Why?
|
| Apoptosis | 1 | 2019 | 400 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2016 | 17 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 39 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 55 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2015 | 24 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2015 | 31 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 51 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 96 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2015 | 120 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 270 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 887 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 50 | 0.020 |
Why?
|
| Glomerular Mesangium | 1 | 2007 | 2 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 509 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 341 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 10015 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 10998 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 129 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 12703 | 0.010 |
Why?
|
| Eye Burns | 1 | 2003 | 3 | 0.010 |
Why?
|
| Photorefractive Keratectomy | 1 | 2003 | 3 | 0.010 |
Why?
|
| Sodium Hydroxide | 1 | 2003 | 6 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 901 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 2003 | 8 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 1946 | 0.010 |
Why?
|
| Lasers, Excimer | 1 | 2003 | 8 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 56 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 99 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 202 | 0.010 |
Why?
|